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AbstrACt
Objective To describe the lived experience of a possible 
prostate cancer overdiagnosis in men who resisted 
recommended treatment.
Design Qualitative interview study
setting Australia
Participants 11 men (aged 59–78 years) who resisted 
recommended prostate cancer treatment because of 
concerns about overdiagnosis and overtreatment.
Outcomes Reported experience of screening, diagnosis 
and treatment decision making, and its impact on 
psychosocial well-being, life and personal circumstances.
results Men’s accounts revealed profound consequences 
of both prostate cancer diagnosis and resisting medical 
advice for treatment, with effects on their psychological 
well-being, family, employment circumstances, identity 
and life choices. Some of these men were tested for 
prostate-specific antigen without their knowledge or 
informed consent. The men felt uninformed about their 
management options and unsupported through treatment 
decision making. This often led them to develop a sense 
of disillusionment and distrust towards the medical 
profession and conventional medicine. The findings 
show how some men who were told they would soon die 
without treatment (a prognosis which ultimately did not 
eventuate) reconciled issues of overdiagnosis and potential 
overtreatment with their own diagnosis and situation over 
the ensuing 1 to 20+ years.
Conclusions Men who choose not to have recommended 
treatment for prostate cancer may avoid treatment-
associated harms like incontinence and impotence, 
however our findings showed that the impact of the 
diagnosis itself is immense and far-reaching. A high 
priority for improving clinical practice is to ensure men 
are adequately informed of these potential consequences 
before screening is considered.
IntrODuCtIOn
The concept and reality of overdiagnosis 
and overtreatment of prostate cancer is 
now widely accepted. Autopsy studies in 
men who died of causes other than prostate 
cancer show that there is a substantial reser-
voir of non-progressive prostate cancer in 
the general male population that increases 
with age.1 Screening for prostate cancer may 
therefore detect non-lethal cancers, leading 
to overdiagnosis and overtreatment. A precise 
estimate of the extent of overdiagnosis in any 
screening programme is difficult, but esti-
mates from the two largest prostate screening 
trials suggest that between 17% and 50% of 
prostate cancers are overdiagnosed.2 Overdi-
agnosed cancers are by definition cancers 
that are not destined to cause morbidity or 
mortality so men with these cancers can only 
be harmed by early detection and unnecessary 
treatment.3 Extensive evidence suggests that 
common, long-lasting harms triggered by the 
prostate-specific antigen (PSA) screening test 
counterbalance or even outweigh the benefits 
(which, if they occur, are delayed 10–15 years 
or more), and most international medical 
bodies advise against PSA screening.2 4 5 Yet a 
significant number of men still undergo PSA 
testing,6 7 many of whom are poorly informed.
Once men receive an elevated PSA test 
result, a biopsy may be performed. Biopsies 
have a high probability of finding prostate 
strengths and limitations of this study
 ► This qualitative study used interviews to explore the 
stories of men, diagnosed with prostate cancer, who 
self-identified as resisting clinical recommendations 
for prostate cancer treatment.
 ► There are considerable challenges to identifying in-
dividuals with cancer who have not been treated and 
show some awareness of the issues of overdiagno-
sis; our study is the first to achieve this in prostate 
cancer.
 ► Our sample was small and the men were well edu-
cated, economically successful and had high health 
literacy, which may have provided increased con-
fidence, means and capacity to challenge medical 
advice.
 o
n
 3 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026960 on 23 May 2019. Downloaded from 
2 McCaffery K, et al. BMJ Open 2019;9:e026960. doi:10.1136/bmjopen-2018-026960
Open access 
cancer that may never have caused clinical symptoms8 9 
and once diagnosed, many men with low-risk, localised 
cancer undergo active treatment immediately.10 Surgery 
(radical prostatectomy) is the most frequent treatment 
method used among men with clinically localised pros-
tate cancer in Australia.11 Mainstay active treatments for 
prostate cancer such as surgery, radiation therapy and 
hormone therapy can result in serious adverse conse-
quences including impotence and incontinence (with 
surgery) and bowel problems (with radiation therapy).12
To reduce the harms of overtreatment,  active surveil-
lance (AS) is endorsed as a management option by a 
number of professional societies for men who present 
with low-risk (PSA<10, Gleason≤6, clinical stage T1–T2) 
prostate cancer.13–16 AS involves closely monitoring the 
tumour (via clinical examinations, imaging, PSA tests 
and prostate biopsies) and acting with curative intent 
if the disease progresses. A 10-year study of >1500 men 
with screen-detected localised prostate cancer found no 
difference in death rates between men who received a 
radical prostatectomy or radiation and those who moni-
tored their disease.17 Numerous qualitative studies have 
explored men’s views regarding the acceptability of an 
AS management approach, as well as men’s experiences 
after opting for AS.18–22 However, we know of no studies 
that have explored men’s choice not to follow any recom-
mended management approach, and the consequences 
for them of so doing.
This study reports on the experiences of men diagnosed 
with prostate cancer between 1 and 20 years ago. They 
declined clinical recommendations for immediate treat-
ment including radical prostatectomy and radiotherapy 
and elected to devise and adopt their own management 
strategies for their prostate disease. Despite the medical 
advice they received at the time of diagnosis these men 
are still alive and are coming to terms with a cancer diag-
nosis and medical advice that implied imminent death if 
the recommended (mostly surgical) treatment was not 
followed. Their narratives provide insight into the hidden 
experience of a potentially ‘unnecessary’ diagnosis of 
prostate cancer, including the psychological and social 
experiences of declining treatment advice, living with a 
slow growing or inconsequential cancer and maintaining 
physical and mental health.
MethODs
Design
This study used qualitative interviews to explore the 
stories of men, diagnosed with prostate cancer, who 
self-identified as resisting clinical recommendations for 
prostate cancer treatment.
Patient and public involvement
The research question was informed by two consumers’ 
personal experience of being diagnosed with prostate 
cancer. The consumers/patients provided advice on 
the study design and results and were involved in study 
recruitment. The findings of the study will be dissemi-
nated to all study participants.
Participants and recruitment
Eleven men initially diagnosed with localised prostate 
cancer, located in three states in eastern Australia (New 
South Wales, Victoria and Queensland).
Men were eligible to participate in the study if they had 
received a biopsy-confirmed diagnosis of prostate cancer 
and initially declined clinical recommendations for treat-
ment. Participants were included if they indicated the 
following to the interviewer: (1) awareness of the issues of 
overdiagnosis and/or overtreatment, (2) expressed doubt 
about their recommended treatment or their manage-
ment decision and (3) had drawn a connection between 
their personal situation and issues of overdiagnosis/
overtreatment.
Most participants were recruited via an information 
and support group (this group was organised by one 
of the participants and is not connected to a charity 
group or any entity that is part of the medical establish-
ment) for men with prostate cancer seeking non-sur-
gical management. Two further eligible participants 
independent of the support group were identified after 
they emailed members of the research team or their 
academic networks to seek advice about prostate cancer. 
Researchers presented information about the study to 
potential participants. All potentially eligible men were 
sent/given an Expression of Interest form. Those who 
returned the form were contacted to arrange an inter-
view. They were invited to share study information with 
other men (snowball sampling). All participants provided 
written informed consent prior to the interview. All men 
who expressed interest in the study and met the inclusion 
criteria agreed to be interviewed and were included in 
the study.
Data collection
An interview guide (online supplementary appendix 1) 
was developed by the research team who have expertise 
in psychology, health communication, public health 
and overdiagnosis. Interviews were conducted by three 
academic researchers (KM, BN, JH) trained in qualitative 
research methods between November 2015 and March 
2016. The interviewers had no immediate personal or 
professional experience with prostate cancer or PSA 
screening, and do not work with men who have prostate 
cancer. Interviews were conducted at participants’ homes, 
their offices, the University of Sydney or Skype (4/11). We 
interviewed as many men as possible who met the inclu-
sion criteria. Since this is a difficult sample to identify, we 
cannot state that we reached thematic saturation.23 Inter-
views lasted between 22 and 70 min and were audio-re-
corded and transcribed verbatim. All clinical data were 
self-reported.
Analysis
The analysis was an iterative process and commenced 
during data collection. Researchers conducted a thematic 
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analysis, aiming to capture the diverse feelings and views 
expressed by the men. The interviewers (KM, BN, JH) 
met regularly to discuss salient observations from their 
interviews, which formed the basis of the initial coding 
framework. All interviewers read a subset of transcripts 
and discussed and revised the coding framework. Once 
the framework was finalised, BN coded all interviews using 
Framework Analysis in Excel.24 KM iteratively checked the 
coding framework within and across themes and partic-
ipants. Themes were summarised and checked by JH 
and KP who added further interpretation and insights. 
Four case studies are presented in the results which were 
selected to represent a range of experiences of diagnosis 
and decision making among the sample. Written consent 
was obtained from the relevant parties for the publication 
of the case studies.
results
The 11 participants were aged 59–78 years at the time of 
interview and 43–76 years (average age 62 years) when 
they were diagnosed with prostate cancer (table 1). In 
Australia, the mean age of prostate cancer diagnosis is 69 
years. One man received a PSA test after reporting urinary 
symptoms, the other 10 were asymptomatic when tested. 
Time since diagnosis: <2 years (n=3), 3–9 years (n=6), 10 
years or more (n=2). The men’s self-reported PSA level 
at the time of diagnosis was between 1.6 and 39.0 with 
Gleason scores between 6 and 9. Nine men held a bach-
elor’s degree or above and one was a medical specialist; 
none had expertise in complementary medicine. All men 
initially declined the treatment recommended to them, 
which was surgery (prostatectomy) for 10/11 men.
The men’s accounts demonstrated broad and signifi-
cant implications resulting from resisting professionally 
recommended treatment for prostate cancer. Here, we 
report on the men’s reasoning for resisting, its impact 
on their personal lives, feeling unsupported and their 
response to the experience, including distrusting 
conventional medicine and questioning decisions made 
(table 2). Four case studies are included which capture 
the individual stories of a selection of men.
Men’s resistance to recommended treatment
The most common explanations that the men gave for 
initially resisting prostatectomy were feeling underin-
formed about their options and, at the same time, feeling 
pressured by their urologist to undergo surgery immedi-
ately (table 1 and 2). These factors together generated 
considerable uncertainty among the men. Several men 
diagnosed within the last 1–5 years said they were offered 
little choice beyond surgery. A number of men expressed 
fear of suffering impotence or incontinence following 
surgery, and generally felt more strongly about avoiding 
the risk of suffering one more than the other. Some were 
more familiar with the potential negative consequences 
of prostatectomy via a family member or friend who had 
undergone surgery and wanted to avoid similar outcomes.
The men’s accounts indicated varied awareness and 
understanding of overdiagnosis and overtreatment. Most 
were familiar with the general concepts including the fact 
that a significant number of men live with untreated and 
Table 1 Participant characteristics and main reasons expressed for resisting recommended treatment
ID
Year of 
diagnosis
Age at 
diagnosis*
Prostate-
specific 
antigen
(ng/mL)
Gleason 
score †
Reasons expressed for resisting recommended treatment
To avoid 
incontinence
To avoid 
impotence
Perceived 
pressure 
from 
urologist
Uncertain 
about 
outcomes/best 
approach
Felt 
underinformed 
about options
Resisted prostatectomy throughout
1 2015 76 5.4 7 (3+4) ✓ ✓ ✓ ✓
2 2009 69 1.6 7 (3+4) ✓ ✓ ✓ ✓
3 2011 60 3.0 9 ✓ ✓
4 1996 43 6.3 6 ✓ ✓ ✓
5 2014 70 12.0 7 (3+4) ✓ ✓ ✓
6 2011 57 6.0 7 (3+4) ✓ ✓ ✓ ✓ ✓
7 2008 54 5.4 Unknown ✓
8 2010 72 10.5 8 (4+4) ✓ ✓ ✓ ✓
Initially resisted but then had prostatectomy (n=2) or radiotherapy (n=1)
9 2015 64 39.0 7 (3+4) ✓ ✓ ✓
10 2001 56 2.0 6 ✓ ✓
11 2013 56 5.5 7 ✓ ✓
† gleason grade included when reported by participant. Blank if unknown. 
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undiagnosed prostate cancer, and that surgery might be 
unnecessary, costly and result in undesirable outcomes. 
Some men had very sophisticated knowledge. A few men 
explicitly stated that they resisted the recommended 
surgery specifically because of concerns about overdi-
agnosis and were aware of debates among the medical 
profession about these issues. Some only encountered 
the concept of overdiagnosis following their own exten-
sive researching after their diagnosis; one participant said 
that he read ten books on the subject.
Men’s resistance had a profound impact on their 
psychological well-being, life decisions and employment
The men resisted treatment even though most of them 
described experiencing considerable pressure to take 
urgent action. Several (n=4/11) were told that they 
would be dead in the next couple of years unless they had 
a prostatectomy and felt threatened and frightened by 
their impending death. Some of the men, immediately 
after their diagnosis, began to prepare for their death by 
‘finalising their affairs’, including extracting themselves 
from business partnerships leading to loss of income and 
change in financial circumstances. But the decision not 
to have the surgery had similarly profound effects on 
their lives as the actual cancer diagnosis. Two men were 
divorced following their diagnosis and attributed this as 
a major cause. One man directly stated that his marriage 
became untenable because his wife did not support his 
decision not to have a prostatectomy. Some men left work 
entirely or modified their employment to make time to 
research and focus on their health and/or to pursue 
alternative treatments overseas.
 I had difficulty dealing with work and my other commit-
ments…I gave it all up, walked out! I decided to walk out 
of my business… I decided to walk out of my partnership… 
(ID4)
Resisting intervention was an intensely psychological 
experience. High anxiety and doubt, a sense of ‘playing 
with fire’, commonly persisted for many years after their 
diagnosis and decision to resist and continued to be 
experienced on a daily basis for some. The worst possible 
consequences of resisting, such as cancer spread and/or 
death, played heavily on the men’s minds.
I still doubt whether I’ve done the right thing, but so far so 
good (ID2)
Case Study 1: Bob*
Bob had been living with a diagnosis of prostate can-
cer for 7 years at the time of interview, and was di-
agnosed aged 69 years. Bob’s doctor began ordering 
annual PSA tests when he was 65, and he went along 
with it because the potential implications of having 
a PSA test were never explained to him. After a few 
years, his PSA was slightly raised (to 1.6), and the 
doctor recommended a biopsy, which he had. He 
described having blood in his urine and a loss of 
Table 2 Summary of key findings with illustrative quotes
Main finding Selected quotes
Men resisted the 
recommended treatment 
for a range of reasons
“Erectile dysfunction would really upset me a great deal” (ID2) (to avoid impotence)
“I was very worried about the possibility of long term incontinence…the idea of having to 
wear pads in my underpants for possibly the rest of my life was not attractive” (ID5) (to avoid 
incontinence)
“(urologist said) based on your history and my examination I think if you don’t have surgery you’ll 
be dead in 5 years’ (ID9); ‘(urologist said) you shouldn’t let this go too long, 3 months max, you 
should be on the table and get rid of it” (ID1) (perceived pressure)
Some men’s resistance 
had a profound impact on 
their psychological well-
being, life decisions and 
employment
“So when someone tells you you’re going to die in 3 years and you make a decision not to have an 
operation—you’ve got to make some life changes…I decided to make massive life changes” (ID4)
“Immediately after the diagnosis I was thinking, ok, so how do I finalise my affairs?” (ID3)
 “It’s a mental thing that you have to deal with every day… it plays on your mind” (ID7)
“3 am in the morning when you wake up and you start thinking of how little of your life you might 
have left” (ID2)
Some men distrusted 
conventional medicine and 
embraced non-mainstream 
treatments
“It just looked like a money making experience for me” (ID7)
“[I] found out a hell of a lot more about the limited choices that conventional medicine offers…
slash, burn or poison, surgery, radiation or chemo” (ID6)
Some men reported lack of 
supportive environments to 
make informed decisions 
about testing or treatment
“He (urologist) said, ‘you don't want to be mucking around with this, you know, it is cancer’…he 
really scared the hell out of me… I thought, I better do this, whatever it is” (ID6)
“I felt very much alone because I didn’t have a doctor who I believed in” (ID2)
Some men, over time, 
reframed the diagnosis and 
decisions made
“I played that game for about 3 years, running around the world [seeking alternative ways of 
healing, treatment]…then I realised nothing was happening, I was fine” (ID4)
“As time went on that level of anxiety, with knowledge… and additional information, and knowing 
how rigged the medical profession operates in this, in this particular sphere, it has sort of gone 
down” (ID6)
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sensitivity following the biopsy, which was unexpect-
ed because he did not know anything about the pos-
sible side effects beforehand. Bob was diagnosed with 
prostate cancer, Gleason score 7. He reported that the 
urologist told him that he would be dead in 3 years 
if he did not have his prostate removed immediate-
ly, and said he could perform the surgery a few days 
away. Bob described feeling immobilised, not being 
able to think; ‘dead in 3 years?’ That’s all I could think 
of. He had just been told he might miss out on seeing 
his grandchildren grow up. He was already aware of 
the risks of prostate surgery and was very concerned 
about erectile dysfunction. When Bob asked for a sec-
ond opinion, he was referred to his urologist’s busi-
ness partner, which prompted him to embark on a 
quest for alternative treatments himself. He did an 
enormous amount of independent research—read-
ing nothing else but medical books for 4 or 5 years, sent 
his pathology to interstate and international special-
ists (at enormous expense), and then flew to New York 
for prostate scans. It was very consuming, in terms of 
time and emotionally. Bob withdrew from part of his 
business because he couldn't work as much, along-
side studying medical texts. He experienced difficulty 
sleeping throughout. He returned to a radiologist in 
New York several more times to monitor any cancer 
progression. According to these scans, Bob’s prostate 
cancer has not changed in any way in the 7 years since 
his diagnosis. Yet it has had a long-lasting impact. He 
continues to suffer sleeplessness, and wonders every 
couple of days whether he has done the right thing by 
not going ahead with the recommended treatment. 
He hopes he can help provide other men with more 
support to make their own decisions, because this isn’t 
riskless.
Case Study 2: Jim
Jim was diagnosed with prostate cancer at the age 
of 54. His story began when he went to his GP for a 
routine prostate check. The GP performed a digital 
rectal examination (DRE) but during the procedure, 
Jim reported that his GP twisted his prostate, which left 
him hospitalised, in agony, and with long-term side 
effects. Two years later, he had another DRE and a 
small nodule was felt by his GP. Jim was referred to a 
urologist for a biopsy and had his first ever PSA test; 
his PSA was elevated (5.4). Jim said he suffered terri-
bly from the biopsy, it was very painful and there was 
blood everywhere, he said if he was more informed he 
would not have agreed to it. The biopsy showed that 
a small proportion of 1 of the 12 samples taken had 
evidence of prostate cancer. The diagnosis was devas-
tating, and it took me a while to get my head around that. 
Jim was referred to an oncologist and another urolo-
gist: he had a good experience with the oncologist, 
but described his consultation with the urologist as 
really off-putting, especially when he was booked in for 
an immediate prostatectomy without any discussion 
about alternative management options. He began an 
extensive investigation of his options, hours and hours 
of research about prostate cancer and its treatment. He 
gathered information from men in a prostate cancer 
support group in a similar position, had ultrasounds 
and MRIs and learnt about overdiagnosis and over-
treatment. At the time of the interview, it had been 
8 years since Jim had decided not to have a prosta-
tectomy. He monitors his prostate cancer with annu-
al ultrasounds and PSA tests and is very happy with 
his decision not to have active treatment. However, 
his decision has had a substantial impact on his life. 
Jim’s wife could not accept his choice not to have the 
surgery, which ultimately contributed to a debilitating 
divorce. He defended his approach as considered, ev-
idence-based, not just going willy nilly down the holistic 
path; yet described the psychological impact of resist-
ing surgery as ongoing, a mental thing that you have to 
deal with every day…it plays on your mind. He advocat-
ed for men to have the opportunity to stop and think 
about things and go, hang on a second, is this the right 
thing to do?
*All names have been changed to preserve 
anonymity. Italics indicate verbatim quotes.
Distrust of conventional medicine and embracing non-mainstream 
treatments
The men reported feeling disillusioned by conventional 
management options and medical opinion (table 2). 
Many of those interviewed felt abandoned by their clini-
cians, specialists and/or the Australian healthcare system 
when they resisted the recommended treatment. Some 
men expressed cynical views of the medical profession 
and speculated that the unequivocal advice for prostatec-
tomy was driven by financial gain. They felt concerned 
that they were not getting the full story, from any clini-
cian, about the range of potential management options.
I am profoundly dissatisfied with what I see as the blinkered 
view of possibilities offered … and the incapacity of these 
people to consider anything outside their carefully regulated 
areas of expertise. (ID5)
In response, they pursued extensive additional testing 
and imaging and dedicated enormous time and energy 
to researching other available options. Almost all of the 
men had actively sought out and embraced an alternative 
management strategy outside of the mainstream system. 
For some this involved herbal supplements, Chinese 
medicine, or major dietary and lifestyle changes. For 
several others, it involved visiting international clinics and 
having ongoing tests and unproven treatments that were 
vastly expensive (eg, hyperthermia: targeted heat therapy 
applied to the area of the prostate). Men reported hearing 
about alternative treatments such as hyperthermia from 
other men in the support group. Several suffered pain 
and discomfort from their procedures, but still perceived 
them as a far better alternative than prostatectomy.
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(Hyperthermia) not an entirely pleasant experience but 
not nearly as debilitating as the radical (prostatectomy) 
(ID5)
lack of supportive environment to make informed decisions 
about testing or treatment
It became evident across the interviews that the men 
felt they were offered limited, if any, time or resources 
to encourage or enable them to make an informed deci-
sion about either PSA testing or treatment. The majority 
of men were not familiar with what a PSA screening test 
was and received no information prior to being screened; 
some did not even know they had been screened until 
they were told their PSA was abnormal.
I had no idea what a PSA test was. The doctor said ‘it’s time’ 
and I went along with it (ID2); I wouldn’t even have known 
what a prostate was about (ID10)
A number of the men shared stories of urologists who 
scheduled their prostatectomies in the same appointment 
that their diagnosis was given. Only one participant was 
advised, after seeking a second opinion, to take his time 
in making a decision about surgery, which he said was 
very helpful at the time. Urologists were often perceived 
to be surgery-focused and with little consideration of what 
the individual man might want or need from the consul-
tation. The men perceived little support or reassurance 
and noted an environment that provided little encour-
agement for them to ask questions or express individual 
priorities. They described real concerns that they wanted 
to be heard—that biopsies and surgery might spread 
cancer, fear of the side effects of surgery, being treated 
unnecessarily—but reported feeling that there was little 
possibility of discussing such matters with their urologist.
Men reported discussing their decision to resist the 
recommended treatment with family (mostly wives/part-
ners and adult children) and friends. Some stated that 
their decision to refuse treatment led to some conflict 
in their relationships while others described their part-
ners as being very supportive. Three of the men reported 
feeling reassured of their decision not to have surgery 
after making contact with other men who had made 
similar decisions (but implied their decision had been 
made before discussing with others).
I’m grateful that I came across—that I did the research and 
came across the people who are in the same boat. (ID7)
reframing the diagnosis and decisions made
At the time of the interview, 8 of the 11 men had continued 
to resist the recommended prostatectomy, suffering no 
physical morbidity from prostate cancer. Several reflected 
on their personal situation and increasing awareness that 
their cancer had not progressed and may not ever do so, 
hence might not be the life-threatening scenario that had 
been presented to them. A number questioned whether 
seeking out alternative ways of healing and treatment 
had helped or whether they would have had the same 
outcome regardless.
I played that game for about 3 years, running around the 
world [seeking alternative ways of healing, treatment]…
then I realised nothing was happening, I was fine. (ID4)
I’ve known for five and a half years that I’ve got cancer in 
me, and I’m still living, walking around, no side effects, no 
nothing… perhaps I will be ok. (ID8)
Some men explicitly considered the relevance of the 
overdiagnosis/overtreatment debate to their circum-
stances. One medically trained participant was highly 
informed about issues of overdiagnosis and overtreat-
ment. He had reluctantly agreed to having a PSA test—a 
‘flawed screening test’—as an insurance requirement, 
after resisting screening for many years. This man, who 
had a prostatectomy after a very high PSA reading, 
wondered if he is one of the ones overdiagnosed or 
whether his diagnosis and surgery saved his life.
There’s a part of me that wonders did I fuck myself up be-
cause I waited three and a half years or did I fuck myself up 
because I had the cleanout…I’ll never know. If I die in the 
next 5 years of metastasis then I’ll know I waited too long… 
again, I’ll never know. I mean, if I die of something else, I 
won’t know if this never would’ve spread anyway, or they 
saved my life. (ID9)
He indicated that he had spent considerable time ques-
tioning and reviewing the decisions he had made.
I had lost a considerable amount of weight…I went to see the 
urologist and he said…you know, because of your PSA, he 
didn’t say because you waited but it was implied, that maybe 
if I had addressed this three and a half years ago… (ID9)
Case Study 3: Ted
Ted was diagnosed with prostate cancer (Gleason 
6) at 56 years, 15 years before this interview. He had 
never had a PSA test until he was referred to a urol-
ogist for a urinary tract infection. He admitted that 
he didn't even know what the prostate was. A PSA of 
2.0 prompted a biopsy. When the urologist told Ted 
that the biopsy had detected prostate cancer, he im-
plied that it was bad, he was pretty grim, and wanted to 
arrange urgent treatment. Ted was very concerned. 
In hindsight he has realised that he (urologist) told me 
things that were not true….that probably it’d spread. He 
received anti-hormonal injections (from which he 
suffered massive hot flushes) in anticipation of de-
layed surgery, because he was in the process of mov-
ing back to Australia after living overseas for some 
years. When he returned, Ted consulted multiple 
urologists about his treatment options, all with vastly 
differing opinions. Despite being told by one urolo-
gist that he would be dead within 5 years, he decided 
not to go ahead with surgery, I wasn't keen to have any 
intervention if it wasn't necessary…I didn't have a lot of 
problem living with cancer. Instead, at the advice of a 
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non-interventionist urologist, he monitored the tu-
mour via biopsies and PSA, which made his first urol-
ogist angry. Ted did eventually have treatment: first, 
brachytherapy, because it did not seem to be very in-
vasive. It was painless and without side effects. Four 
years later, he had external beam radiation, again 
with minimal side effects. After 14 years of living 
with prostate cancer, Ted finally had a prostatectomy 
at the advice of his urologist after his PSA doubled 
(PSA increased from 2 to 4), despite originally being 
firmly against intervention. He describes the flow on 
effects that can eventuate from a positive PSA test: 
you’re damned if you do and it’s a damned if you don't. 
You know, because you’re in a dilemma and you really don't 
know how serious this dilemma is. ‘…I stayed with it—well 
I hadn’t stayed with it I had it for 14 years and I eventually 
did have the treatment…I did have to have it in the end’. 
He said over the 14 years he had plenty of time to find 
out about the possible side effects of surgery, most of 
which he didn't want. Following the prostatectomy, 
he had a lot of anal pain, lacks faecal control, and is 
impotent. He doesn't regret postponing the surgery. 
But if you come to me in 5 years’ time and I’m almost dead 
because I didn’t have the surgery earlier I might have a dif-
ferent idea, mightn’t I? … ‘I hope I have nothing to regret, 
we’ll see in 3 or 4 years’ time but I’m getting past the 5 years 
that (the urologist) reckoned I would have’ (to live).
Another man strongly resisted the recommended 
management for a number of years following an elevated 
PSA result due to awareness of the harms of overdiagnosis 
but then reported having developed secondary cancer. He 
subsequently had mixed views on overdiagnosis because 
he is living with a progressed cancer that may have bene-
fited from earlier detection. He questioned whether he 
should have agreed to further testing and treatment 
sooner.
All that overdiagnosis is to try and save the one, turns 
out I’m the one so, I have mixed views on it. (ID11)
Both men showed signs of self-blame for their deci-
sion-making. The uncertainty about whether the deci-
sions they had made were the right ones seemed to play 
heavily on their minds and was ultimately unresolvable.
Case study 4: Peter
Peter was diagnosed with prostate cancer (Gleason 
7) in 2013 at 56 years. He had for many years resist-
ed having a biopsy, which was recommended to him 
following an elevated PSA (but normal DRE). He 
described a urologist trying to force me to have a biopsy 
against my better judgement. He felt that the informa-
tion about the wisdom of having a biopsy done simply on 
the basis of a rising PSA was conflicting, and had heard 
concerns about overtesting and overdiagnosis on the 
radio. He recalled at the time thinking I probably didn’t 
have a serious problem…I thought the odds were still in my 
favour. Instead, Peter chose to undergo ultrasounds of 
his prostate and had a new procedure (laser ablation) 
in New York: a radical new treatment having great suc-
cess. He considered it his best shot at having the treatment 
done and dusted. It cost US$30 000 (which seemed like a 
good bet at the time…In hindsight I’d love to get my mon-
ey back if I could) and was extremely uncomfortable and 
undignified, intrusive. Initially, the specialists pretty well 
declared the whole process a success, and he was told to go 
home and you shouldn’t have any more worries. However, 
12 months later his PSA had risen to 24, so I clearly 
had a bit of a problem. A full body CAT scan revealed a 
suspicious area in his hip, which was potentially a sec-
ondary cancer. The specialist’s recommendation was 
for Peter to have hormone treatment—which he re-
ally struggled with—and then fairly aggressive radiation 
treatment. A radical prostatectomy was not an option 
after he had had the laser treatment. His thought 
process at the time was, I’d pursued the sort of alternative 
treatment path thinking at the time that it was unlikely I 
had a severe problem anyway…I was sort of just being a little 
cautious. But, it turns out I was in that small percentage 
that had a serious growth. The alternative treatment hadn’t 
worked. By this stage he had realised that he couldn’t 
afford to screw around with this anymore, his efforts trying 
to manage my own prognosis had been unsuccessful and 
he resorted to finding the best specialist he could. 
Peter described the whole process as a rollercoaster. 
At the time of interview, it had been 2 years since his 
radiation therapy. He continues to have side effects 
including some impotence and rectal bleeding. Peter 
had to reduce his working hours, it has a real impact, 
a big impact. He suffers from anxiety attacks and de-
scribed sometimes being almost petrified with fear. The 
prostate cancer causes significant worry, I’m still con-
cerned that it’s probably going to get me…I suspect that it’s 
a matter of time. Peter admitted that with hindsight he 
would have changed my course of action… clearly I should 
have had a biopsy done. He believes that it was a good 
decision to leave the first urologist and not to have 
had a biopsy straight away, but would have sought bet-
ter specialist advice sooner, and had a prostatectomy 
if it was recommended. Peter continues to believe 
that there is some truth in the overdiagnosis and over-
treatment argument, but turns out I’m in that very small 
percentage…all that overdiagnosis is to try and save the one, 
turns out I’m the one, so I have mixed views on it…I’d be in 
much more serious trouble had I not had the treatment.
DIsCussIOn
This study provides important, relevant insight into the 
lived experience of possible overdiagnosis. It reveals the 
substantial and sustained burden on men’s lives as they 
continue to live with a potentially inconsequential cancer 
diagnosis alongside their decision to decline recom-
mended treatment. Such accounts are rarely reported 
in the literature, hidden in part because we are mostly 
unable to identify individuals who have been feel they 
may have been overdiagnosed, given that it is rare to 
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leave cancer untreated. Importantly, these men’s views 
contrast with beliefs of many patients with cancer that 
their diagnosis was life-saving or life affirming and reveal 
the profound negative psychosocial impact of diagnosis.
Clinicians have traditionally underappreciated the 
adverse impact of prostate cancer diagnosis and treat-
ments thus resulting in limited visibility of these effects 
in the medical literature until recent years.12 25 26 Previous 
work with clinicians shows that a strong driver of the 
continued use of PSA testing is the fear of missing a 
patient’s cancer.27–29 However, this fails to recognise the 
potential downstream consequences on men of unneces-
sary testing and overdiagnosis.
Particularly notable in this study were two men who 
had deliberately delayed testing and treatment because 
of concerns about overdiagnosis and overtreatment. 
They both eventually, reluctantly, received cancer treat-
ment (one presented symptomatically with a secondary 
cancer, the other had a dramatic increase in PSA). At 
the time of interview, they described significant uncer-
tainty and angst about their decision to delay. Both had 
a very sophisticated understanding of overdiagnosis and 
recognised that they would never know if they had made 
the right decision. The guilt, questioning and uncertainty 
that remains with that knowledge was significant and 
unresolvable.
For some men in this sample, feeling uninformed 
and pressurised by specialists were described as more 
important reasons to resist surgery than avoidance of 
potential treatment side effects . These findings demon-
strate the real-life consequences of violations of the 
ethical principle of autonomy, with men reporting being 
tested for PSA without their knowledge and being offered 
limited information about treatment. This is consistent 
with existing literature suggesting that many Austra-
lian men do not have treatment options for early pros-
tate cancer adequately explained to them, with urgent 
surgical treatment still frequently encouraged.30 Research 
from the US suggests a similar picture with informed 
decision-making rare,31 even when decision support is 
provided.32–34 Recent findings from the US and Australia 
similarly suggest shared decision-making around PSA 
testing and prostate cancer treatment is limited.30 33 35
Poor public understanding of PSA screening and 
overdiagnosis is common,36–38 and likely exacerbated by 
lower levels of education and health literacy.39 There is 
evidence that the harms of overdiagnosis and overtreat-
ment are rarely explained to patients.40 41 Overdiagnosis 
is a challenging concept to communicate,36 42 yet studies 
of prostate screening show that men want to be told about 
it.43 Importantly, some research suggests that informing 
men about their options early, including the option of 
conservative treatment, might help mitigate long-term 
decision regret.44 Continued efforts to better communi-
cate, inform and empower men to avoid the implications 
described in this study are essential.
Men in this study felt inadequately prepared and 
unsupported from the point of the initial PSA screening 
test, to biopsy and treatment decision-making. A qualita-
tive study of individuals who self-identified as having an 
overdiagnosed thyroid cancer and decided not to inter-
vene with surgical treatment revealed similar findings to 
this study.45 Their experience was characterised by feel-
ings of isolation and ongoing anxiety resulting from lack 
of social and healthcare system acceptance and support 
for their decision to resist treatment. The view that treat-
ment is always needed and life-saving is normalised such 
that attitudes contrary to that norm may be dismissed and 
rejected.
Although this study cannot discern causation, it could 
be that distrust in conventional medicine may ensue 
from feeling inadequately informed and unsupported. It 
is noteworthy that many of the men pursued expensive 
alternative tests and treatments that have little current 
supporting evidence of efficacy, with a strong desire to ‘do 
something’. This revelation is not surprising given that a 
recent Australian study documented increased distress 
and anxiety in men who opted to monitor their low-risk 
prostate cancer rather than actively treat it,46 and a 5-year 
follow-up study found that 23% of men discontinued AS 
despite no evidence of cancer progression.47
There was a wide range (1 to 20+ years) of time since 
diagnosis when the interviews took place. These find-
ings should be considered in the context of changes 
over time and current management of localised prostate 
cancer. Prostate screening, diagnosis and management 
strategies have changed rapidly over the years and we 
recognise that shifting policy, service provision and infor-
mation resources (eg, internet) over that time might 
have impacted on men’s experiences and perceptions 
reported here. Changing technologies and new knowl-
edge have advanced the field. Active surveillance, which 
is now endorsed as a management option for men with 
low-risk disease, was not a common option when some 
men in this study were first diagnosed. Uptake of AS for 
low-risk prostate cancer is increasing in Australia with 
current estimates indicating around 36% of men with 
low-risk prostate cancer accept it.48 Importantly, several 
recently diagnosed men in our sample reported that AS 
was not discussed with them as a potential option. 
strengths and limitations
To our knowledge, this is the first study to document how 
men diagnosed with prostate cancer reconcile issues of 
overdiagnosis and overtreatment and make sense of these 
issues in relation to their own situation. There are consid-
erable challenges to identifying individuals with cancer 
who have chosen not to be treated and show some aware-
ness of the issues of overdiagnosis. Our study is the first to 
achieve this in prostate cancer.
Our sample was small and the men were well educated, 
economically successful and had high health literacy. This 
may have provided increased confidence and capacity to 
challenge medical advice, and to seek out and understand 
complex health information and concepts such as overdi-
agnosis and overtreatment. Recent evidence suggests that 
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men with higher education and income in Australia and 
the USA are more likely to have PSA testing and therefore 
be diagnosed with prostate cancer.49 50 Our participants 
were initially recruited through a support group founded 
by men who had resisted surgical management of pros-
tate cancer. Although resisting treatment altogether may 
not be a common experience, the concerns and reactions 
of these men to their situation would likely be salient for 
the many men with localised prostate cancer who find 
themselves facing this unpleasant dilemma. Many of the 
cancer-related fears and uncertainties expressed by the 
men in our sample are similar to those reported in studies 
from North America51 52 and are likely to transcend inter-
national borders. They therefore provide important leads 
for further research internationally.
We note that recall bias is possible given that it had 
been many years since diagnosis for some of the men in 
this sample, in addition to the impact of a cancer diag-
nosis on information retention.53 However, men’s past 
and current perceptions of how their diagnosis and deci-
sions were made still affect them, and are meaningful and 
relevant to understand.
COnClusIOn
Widespread overdiagnosis of prostate cancer remains 
an important health problem.2 The immense psychoso-
cial consequences of a potentially unnecessary diagnosis 
must be taken into account in any discussions and deci-
sions about PSA screening. These findings underscore 
the need to respect the ethical principle of autonomy by 
supporting men to make informed decisions about both 
screening and treatment in a clinical situation laden with 
so many uncertainties. Ultimately, the way to address 
the psychosocial burden of overdiagnosis and overtreat-
ment of localised prostate cancer (especially low risk 
prostate cancer) is to better inform men and move deci-
sion making upstream, prior to diagnosis and prior to 
screening. More efforts to support informed choice and 
shared decision making at the point of PSA testing are 
needed.
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